Innosys announced that its 3D-printed Unispace Stand-Alone C Cage has successfully treated degenerative disc patients in the United States for the first time, following its FDA 510(k) approval in April.
CG Bio is the largest shareholder of Innosys since February, when the company confirmed its investment after completing an equity acquisition.
The Unispace Stand-Alone C Cage is designed to not only restore disc height and angle, but also features a porous titanium structure akin to human spongy bone.
“This biocompatible design improves resistance to corrosion and enhances stability within the body over extended periods,” said an Innosys official. “The device also bonds more quickly and securely with surrounding bone tissue compared to other metals, facilitating rapid osseointegration and promoting faster bone fusion post-surgery.”
“What sets Unispace apart is its stand-alone design, which integrates the damaged disc and securing screw into a single cohesive unit,” the official explained. This eliminates the need for a separate cervical plate, as the screws are incorporated directly into the cage.
The cage features a double-locking mechanism, including an elastic band automatic locking system that first secures the screws and then attaches an additional locking plate to minimize screw loosening and enhance fixation strength.
Innosys is expanding Unispace’s global footprint with a particular focus on the U.S. medical device market. After receiving FDA 510(k) approval in April, the company plans to enhance its market share, especially within ambulatory surgery centers in the U.S. Additionally, Innosys said it is preparing to introduce Unispace in Korea.
Innosys announced that its 3D-printed Unispace Stand-Alone C Cage has successfully treated degenerative disc patients in the United States for the first time, following its FDA 510(k) approval in April.
CG Bio is the largest shareholder of Innosys since February, when the company confirmed its investment after completing an equity...
Innosys announced that its 3D-printed Unispace Stand-Alone C Cage has successfully treated degenerative disc patients in the United States for the first time, following its FDA 510(k) approval in April.
CG Bio is the largest shareholder of Innosys since February, when the company confirmed its investment after completing an equity acquisition.
The Unispace Stand-Alone C Cage is designed to not only restore disc height and angle, but also features a porous titanium structure akin to human spongy bone.
“This biocompatible design improves resistance to corrosion and enhances stability within the body over extended periods,” said an Innosys official. “The device also bonds more quickly and securely with surrounding bone tissue compared to other metals, facilitating rapid osseointegration and promoting faster bone fusion post-surgery.”
“What sets Unispace apart is its stand-alone design, which integrates the damaged disc and securing screw into a single cohesive unit,” the official explained. This eliminates the need for a separate cervical plate, as the screws are incorporated directly into the cage.
The cage features a double-locking mechanism, including an elastic band automatic locking system that first secures the screws and then attaches an additional locking plate to minimize screw loosening and enhance fixation strength.
Innosys is expanding Unispace’s global footprint with a particular focus on the U.S. medical device market. After receiving FDA 510(k) approval in April, the company plans to enhance its market share, especially within ambulatory surgery centers in the U.S. Additionally, Innosys said it is preparing to introduce Unispace in Korea.
Copy to clipboard 
